Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022
November 08, 2022 17:30 ET
|
Medexus Pharmaceuticals Inc
Results reflect strong growth across all leading prescription products, including IXINITY, Rupall, and Gleolan Management to host conference call at 8:00 AM Eastern Time on Wednesday, November 9,...
Medexus Schedules Second Quarter 2023 Conference Call
November 02, 2022 08:00 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, November 9,...
Medexus Announces Preliminary Revenue Results for Second Fiscal Quarter 2023
October 06, 2022 07:30 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for...
Medexus and MidCap Agree to Increase in MidCap’s Revolving Loan Commitment Amount
September 29, 2022 17:05 ET
|
Medexus Pharmaceuticals Inc
Medexus’s borrowing capacity under its revolving credit facility increases byUS$5.0 million, from US$20.0 million to US$25.0 million Transaction strengthens Medexus’s balance sheet, providing...
Medexus Provides Update on Treosulfan NDA Resubmission and Provides Business Update
September 19, 2022 08:00 ET
|
Medexus Pharmaceuticals Inc
FDA requests further information from medac, continues to engage with treosulfan NDA Medexus continues to focus on maintaining momentum and growth in its North American on-market portfolio, and is...
Medexus Holds Annual Meeting of Shareholders and Announces Election of Board of Directors
September 15, 2022 17:05 ET
|
Medexus Pharmaceuticals Inc
All director nominees reelected for the coming yearAll other proposals also approved by shareholders TORONTO and CHICAGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus)...
Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022
August 08, 2022 17:00 ET
|
Medexus Pharmaceuticals Inc
Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2 Treosulfan NDA resubmitted to the FDA, regulatory milestone payments deferred to October 2023 ...
Medexus Schedules First Quarter 2023 Conference Call
August 02, 2022 17:00 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 9, 2022...
Treosulfan NDA Resubmitted to FDA
July 25, 2022 07:00 ET
|
Medexus Pharmaceuticals Inc
FDA decision expected within six months of acceptancePivotal phase 3 clinical trial of treosulfan met primary endpoint and key secondary endpoints TORONTO and CHICAGO, July 25, 2022 (GLOBE...
Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)
June 22, 2022 17:50 ET
|
Medexus Pharmaceuticals Inc
TORONTO and CHICAGO, June 22, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update...